Korean J Pain.  2020 Jul;33(3):201-207. 10.3344/kjp.2020.33.3.201.

Recombinant zoster vaccine (Shingrix^®): a new option for the prevention of herpes zoster and postherpetic neuralgia

• Singh G
• Song S
• Choi E
• Lee PB
• Nahm FS

• KMID: 2504065
• DOI: http://doi.org/10.3344/kjp.2020.33.3.201

Abstract

Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax^®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix^®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.

Keyword

Herpes Zoster; Herpes Zoster Vaccine; Immunity, Humoral; Neuralgia, Postherpetic; Pain; Vaccines, Attenuated; Vaccines, Subunit; Vaccines, Synthetic

Reference

1. Jeon YH. 2015; Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain. 28:177–84. DOI: 10.3344/kjp.2015.28.3.177. PMID: 26175877. PMCID: PMC4500781.

2. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. 2000; Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 342:635–45. DOI: 10.1056/NEJM200003023420906. PMID: 10699164.

3. Johnson RW, Rice AS. 2014; Clinical practice. Postherpetic neuralgia. N Engl J Med. 371:1526–33. DOI: 10.1056/NEJMcp1403062. PMID: 25317872.

4. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. 2015; Varicella zoster virus infection. Nat Rev Dis Primers. 1:15016. DOI: 10.1038/nrdp.2015.16. PMID: 27188665. PMCID: PMC5381807.

5. Shrestha M, Chen A. 2018; Modalities in managing postherpetic neuralgia. Korean J Pain. 31:235–43. DOI: 10.3344/kjp.2018.31.4.235. PMID: 30310548. PMCID: PMC6177534.

6. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. 2011; Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 52:332–40. DOI: 10.1093/cid/ciq077. PMID: 21217180.

7. Chernev I, Gomez E. 2014; Herpes zoster and diabetes mellitus. Korean J Pain. 27:92. DOI: 10.3344/kjp.2014.27.1.92. PMID: 24478910. PMCID: PMC3903810.

8. Kimberlin DW, Whitley RJ. 2007; Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 356:1338–43. DOI: 10.1056/NEJMct066061. PMID: 17392303.

9. Hong MJ, Kim YD, Cheong YK, Park SJ, Choi SW, Hong HJ. 2016; Epidemiology of postherpetic neuralgia in Korea: an electronic population health insurance system based study. Medicine (Baltimore). 95:e3304. DOI: 10.1097/MD.0000000000003304. PMID: 27057902. PMCID: PMC4998818.

10. Kim KH. 2013; Herpes zoster vaccination. Korean J Pain. 26:242–8. DOI: 10.3344/kjp.2013.26.3.242. PMID: 23861997. PMCID: PMC3710937.

11. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, et al. 2016; Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 375:1019–32. DOI: 10.1056/NEJMoa1603800. PMID: 27626517.

12. Weller TH, Witton HM, Bell EJ. 1958; The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro. J Exp Med. 108:843–68. DOI: 10.1084/jem.108.6.843. PMID: 13598816. PMCID: PMC2136922.

13. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. 1974; Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 2:1288–90. DOI: 10.1016/S0140-6736(74)90144-5.

14. Wang L, Zhu L, Zhu H. 2016; Efficacy of varicella (VZV) vaccination: an update for the clinician. Ther Adv Vaccines. 4:20–31. DOI: 10.1177/2051013616655980. PMID: 27551429. PMCID: PMC4976721.

15. Sanford M, Keating GM. 2010; Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 27:159–76. DOI: 10.2165/10489140-000000000-00000. PMID: 20104941.

16. Syed YY. 2018; Recombinant zoster vaccine (Shingrix^®): a review in herpes zoster. Drugs Aging. 35:1031–40. DOI: 10.1007/s40266-018-0603-x. PMID: 30370455.

17. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. 2019; Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 19:988–1000. DOI: 10.1016/S1473-3099(19)30163-X.

18. Warrington R, Ismail S. National Advisory Committee on Immunization (NACI). 2018; Summary of the NACI update on herpes zoster vaccines. Can Commun Dis Rep. 44:220–5. DOI: 10.14745/ccdr.v44i09a06. PMID: 31015813. PMCID: PMC6449089.

19. Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, et al. 2019; Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 19:1001–12. DOI: 10.1016/S1473-3099(19)30310-X.

20. Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, et al. 2017; Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis. 65:1174–82. DOI: 10.1093/cid/cix484. PMID: 29126292.

21. Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, et al. 2017; Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 35:1764–9. DOI: 10.1016/j.vaccine.2016.10.055. PMID: 28268074.

22. Cohen JI. 2008; Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis. 197(Suppl 2):S237–41. DOI: 10.1086/522129. PMID: 18419403. PMCID: PMC2679676.

23. Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, et al. 2018; Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 17:619–34. DOI: 10.1080/14760584.2018.1495565. PMID: 30028651.

24. Choi WS. 2013; Herpes zoster vaccine in Korea. Clin Exp Vaccine Res. 2:92–6. DOI: 10.7774/cevr.2013.2.2.92. PMID: 23858399. PMCID: PMC3710929.

25. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. 2012; Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 54:922–8. DOI: 10.1093/cid/cir970. PMID: 22291101. PMCID: PMC4542655.

26. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. 2005; A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 352:2271–84. DOI: 10.1056/NEJMoa051016. PMID: 15930418.

27. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. 2012; Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 55:1320–8. DOI: 10.1093/cid/cis638. PMID: 22828595. PMCID: PMC4542855.

28. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. 2015; Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 60:900–9. DOI: 10.1093/cid/ciu918. PMID: 25416754. PMCID: PMC4357816.

29. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. 2016; Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 213:1872–5. DOI: 10.1093/infdis/jiw047. PMID: 26908728.

30. Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, et al. 2018; Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 187:161–9. DOI: 10.1093/aje/kwx245. PMID: 29309521. PMCID: PMC6018833.

31. Zussman J, Young L. 2008; Zoster vaccine live for the prevention of shingles in the elderly patient. Clin Interv Aging. 3:241–50. DOI: 10.2147/CIA.S1225. PMID: 18686747. PMCID: PMC2546469.

32. Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N. 2017; Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 16:55–63. DOI: 10.1080/14760584.2016.1213632. PMID: 27448771.

33. Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM. 2006; Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol. 80:9481–96. DOI: 10.1128/JVI.00533-06. PMID: 16973553. PMCID: PMC1617235.

34. Symoniak MR, Farrokh P, Gandhi MA, Slish JC. 2018; Herpes zoster subunit vaccine for the prevention of herpes zoster. Am J Health Syst Pharm. 75:861–9. DOI: 10.2146/ajhp170399. PMID: 29880523.

35. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. 2015; Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 372:2087–96. DOI: 10.1056/NEJMoa1501184. PMID: 25916341.

36. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, et al. 2018; Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 14:1370–7. DOI: 10.1080/21645515.2018.1442162. PMID: 29461919. PMCID: PMC6037441.

37. López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al. 2019; Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 37:2482–93. DOI: 10.1016/j.vaccine.2019.03.043. PMID: 30935742.

38. McGirr A, Widenmaier R, Curran D, Espié E, Mrkvan T, Oostvogels L, et al. 2019; The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis. Vaccine. 37:2896–909. DOI: 10.1016/j.vaccine.2019.04.014. PMID: 30982636.

39. Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, et al. 2017; Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 216:1343–51. DOI: 10.1093/infdis/jix482. PMID: 29029122. PMCID: PMC5853346.

40. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. 2018; Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 67:103–8. DOI: 10.15585/mmwr.mm6703a5. PMID: 29370152. PMCID: PMC5812314.

41. German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI). 2017; Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany: statement of the. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 60:1162–79. DOI: 10.1007/s00103-017-2618-6. PMID: 28879392.

42. Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, et al. 2019; Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 62:352–76. DOI: 10.1007/s00103-019-02882-5. PMID: 30848293.

43. Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A. 2019; Varicella zoster virus vaccines: an update. Immunotargets Ther. 8:15–28. DOI: 10.2147/ITT.S176383. PMID: 31497569. PMCID: PMC6689529.